Gyre Therapeutics (GYRE) Enterprise Value (2010 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Enterprise Value of -$14.1 million for Q1 2026, down 179.83% year-over-year from $17.7 million in Q1 2025, and down 250.91% quarter-over-quarter from -$4.0 million in Q4 2025.
Gyre Therapeutics (GYRE) Enterprise Value (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Enterprise Value for 17 consecutive years, with -$14.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value fell 179.83% year-over-year to -$14.1 million; the TTM figure through Mar 2026 stood at -$14.1 million (down 179.83% YoY), while the FY2025 annual figure was -$4.0 million, down 147.77% from the prior year.
- Enterprise Value retreated to -$14.1 million in Q1 2026 per GYRE's latest filing, from -$4.0 million in the prior quarter.
- Across five years, Enterprise Value topped out at $29.7 million in Q4 2022 and bottomed at -$75.4 million in Q2 2022.
- Historically, Enterprise Value has averaged -$6.2 million across 5 years, with a median of -$4.0 million in 2025.
- Annual changes were most pronounced in 2024 — Enterprise Value jumped 556.42% — and 2025, when it sank 341.0%.
- Gyre Therapeutics' Enterprise Value stood at $29.7 million in 2022, then slumped by 35.36% to $19.2 million in 2023, then slumped by 56.11% to $8.4 million in 2024, then tumbled by 147.77% to -$4.0 million in 2025, then slumped by 250.91% to -$14.1 million in 2026.
- Business Quant data shows GYRE's Enterprise Value at -$14.1 million in Q1 2026, -$4.0 million in Q4 2025, and -$24.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | -22.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -22.84 Mn |
| Mar 31, 2026 | -14.12 Mn |
| Dec 31, 2025 | -4.03 Mn |
| Sep 30, 2025 | -24.51 Mn |
| Jun 30, 2025 | -16.96 Mn |
| Mar 31, 2025 | 17.69 Mn |
| Dec 31, 2024 | 8.43 Mn |
| Sep 30, 2024 | 10.17 Mn |
| Jun 30, 2024 | 7.90 Mn |
| Mar 31, 2024 | 15.88 Mn |
| Dec 31, 2023 | 19.20 Mn |
| Sep 30, 2023 | -2.23 Mn |
| Jun 30, 2023 | -11.53 Mn |
| Mar 31, 2023 | -8.10 Mn |
| Dec 31, 2022 | 29.70 Mn |
| Sep 30, 2022 | -23.09 Mn |
| Jun 30, 2022 | -75.39 Mn |
| Mar 31, 2022 | -34.82 Mn |
| Dec 31, 2021 | -46.85 Mn |
| Sep 30, 2021 | -69.87 Mn |